Loading clinical trials...

Antithrombin III in Infectious Disease Caused by COVID-19 | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Antithrombin III in Infectious Disease Caused by COVID-19

Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19)

NCT04899232•Enrique Ginzburg

View on ClinicalTrials.gov

Summary

The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. \>18y of age,
•2. Subject or proxy who can provide informed consent
•3. Positive SARS-COV-2 by Polymerase Chain Reaction (PCR) or as determined by clinical team

Exclusion Criteria

•1. Adults or Proxy unable to consent
•2. Individuals who are not yet adults (infants, children, teenagers)
•3. Pregnant women
•4. Prisoners
•5. Patients expected to die within 24 hours or with a "do not resuscitate" order,
•6. Multi-organ failure,
•7. History of hypersensitivity or allergy to any component of the study drug,
•8. Ongoing massive surgical or unexplained bleeding,
•9. History of bleeding or clotting disorder,
•10. Severe traumatic brain injury (Glasgow Coma Scale \<6),
+4 more criteria

Locations (1)

University of Miami

Miami, Florida, United States

Key Dates

Start Date

July 6, 2021

Primary Completion Date

March 31, 2022

Completion Date

March 31, 2022

Last Updated

September 7, 2022

Enrollment

ACTUAL participants

Conditions

Antithrombin III DeficiencyCovid19

Interventions

Antithrombin III

DRUG

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Antithrombin III in Infectious Disease Caused by COVID-19

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy